Briacell Therap (NASDAQ:BCTX) Announces Quarterly Earnings Results

Posted by Latisha Jones on Jun 11th, 2026

Briacell Therap (NASDAQ:BCTX – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.99) earnings per share for the quarter, Zacks reports.

Briacell Therap Stock Performance

BCTX opened at $2.88 on Thursday. The firm has a market cap of $25.06 million, a P/E ratio of -0.12 and a beta of 1.21. The firm has a 50-day moving average of $3.87 and a 200 day moving average of $5.39. Briacell Therap has a fifty-two week low of $2.88 and a fifty-two week high of $36.00.

Hedge Funds Weigh In On Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC bought a new position in shares of Briacell Therap (NASDAQ:BCTX – Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned 1.63% of Briacell Therap as of its most recent SEC filing. Hedge funds and other institutional investors own 15.42% of the company’s stock.

Analyst Upgrades and Downgrades

BCTX has been the topic of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a report on Monday, April 20th. Wall Street Zen upgraded shares of Briacell Therap from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Check Out Our Latest Stock Report on Briacell Therap

Briacell Therap Company Profile

(Get Free Report)

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.